Stanley C. Erck

Stanley C. Erck

DirectoratNovavax· In proxies 2021–2025

Pay in FY2023-54% from the year before · Novavax stock -53.3% the same year

Stanley C. Erck was paid $3.8M in FY2023 (Dec), down 54%. Novavax stock fell 53.3% that year.

Pay$100 in the stock at the end of FY20 → $4
Pay is from the Summary Compensation Table of each Novavax proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. MaxcytePublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. NovavaxPublic company · 5 yr
    • Former President and CEO2021 – Present · 5 yrStock in role -92%

Roles come from the proxy statements of each company.

Boards1

  • MaxcyteDirector · 20 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?